{
    "clinical_study": {
        "@rank": "36839", 
        "arm_group": [
            {
                "arm_group_label": "mild cognitive impairment"
            }, 
            {
                "arm_group_label": "mild to moderate cognitive impairment"
            }, 
            {
                "arm_group_label": "normal or control group"
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of this study is to create new retinal imaging processing software useful for the\n      development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's\n      disease (AD)."
        }, 
        "brief_title": "Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease", 
        "condition": [
            "Mild Cognitive Impairment", 
            "Mild to Moderate Cognitive Impairment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alzheimer Disease", 
                "Cognition Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Result of the standard neuropsychological assessment\n\n          2. Are men or postmenopausal women, at least 55 years of age. Postmenopausal women are\n             defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who\n             have been amenorrheic for at least 2 years;\n\n          3. Fluency in English\n\n          4. Participants in mild cognitive impairment (MCI)/prodromal and mild-to-moderate\n             dementia groups must assign a surrogate for purposes of informed consent and help\n             with protocol compliance.\n\n        Exclusion Criteria:\n\n          1. Known or suspected diagnosis of non-AD, associated dementia;\n\n          2. Major ophthalmologic comorbidities: Ruptured globe, retinal vascular occlusive\n             disease, retinal artery occlusion, anterior ischemic optic neuropathy, media\n             opacification due to corneal abnormalities or cataract that prevent ocular and OCT\n             examination, glaucoma, wet (neovascular) age-related macular degeneration, history of\n             intravitreal injections, and macular edema. If two eyes satisfy the inclusion\n             criteria, both eyes will be included in the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Normal controls and patients with mild, mild to moderate cognitive impairment"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937221", 
            "org_study_id": "Pro00047227"
        }, 
        "intervention": {
            "arm_group_label": [
                "mild cognitive impairment", 
                "mild to moderate cognitive impairment", 
                "normal or control group"
            ], 
            "description": "Intervention same to all groups.", 
            "intervention_name": "spectral-domain optical coherence tomography (SD-OCT)", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "mild cognitive impairment", 
            "mild to moderate cognitive impairment"
        ], 
        "lastchanged_date": "February 10, 2014", 
        "location": {
            "contact": {
                "email": "heather.whitson@dm.duke.edu", 
                "last_name": "Heather Whitson, MD MHS", 
                "phone": "919-660-7514"
            }, 
            "contact_backup": {
                "email": "nora.lad@dm.duke.edu", 
                "last_name": "Eleonora Lad, MD PhD", 
                "phone": "9196844359"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Heather Whitson, MD, MHS", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Eleonora Lad, MD,PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease", 
        "overall_official": [
            {
                "affiliation": "Duke University", 
                "last_name": "Heather Whitson, MD, MHS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Duke University", 
                "last_name": "Eleonora Lad, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline.", 
                "measure": "Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "The study will determine the significance of difference in NFL/GCL score between the AD subject groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have another measurement taken at 12 months.", 
                "measure": "NFL/GCL abnormality score", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The study will determine the significance of difference in peripheral drusen/amyloid plaque score between the AD subject groups at baseline.", 
                "measure": "Drusen/plaque score", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "The study will determine the significance of difference in peripheral drusen/amyloid plaque score between the AD subjects groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have a second measurement at 12 months.", 
                "measure": "Drusen/plaque score", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The study will determine the significance of difference in total drusen area between the AD subject groups at baseline.", 
                "measure": "Total drusen area", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "description": "The study will determine the significance of difference in total drusen area between the AD subject groups at baseline. Dependent on baseline results, some subjects may have the opportunity to have a second measurement taken at 12 months.", 
                "measure": "Total drusen area", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Duke Institute for Brain Sciences", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Alzheimer's Association", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}